Vitrolife strengthens organization in business development

Vitrolife has appointed the Board member Fredrik Mattsson as head of the newly established New Business and Strategic Development function in order to strengthen the company’s business development. In conjunction with the new operative role, Fredrik Mattsson is stepping down as a Board member of Vitrolife AB and Henrik Blomquist, CEO of Bure Equity AB, will assume the role of co-opted Board member up until the next Annual General Meeting.

Fredrik Mattsson has many years’ experience of business development, for example in the medical device sector, and takes up his new position on September 15. When he takes up this position he will step down from his employment as Investment Director at Bure Equity AB. The newly established New Business and Strategic Development function aims to support the company’s growth strategy and Fredrik Mattsson will be part of the company’s executive management.  

September 12, 2018
Gothenburg
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Carsten Browall, Chairman of the Board, tel 46 702 55 65 32

This information is information that Vitrolife AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 am CET on September 12, 2018.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 370 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Tags: